March 2021 • PharmaTimes Magazine • 4-5

Contents

News Review

7. NHS

Features

The future of the pharma-NHS dynamic

Veeva’s predictions for the life sciences industry in 2021

How the science of microbiomes will increasingly contribute to research outcomes

The relationship between the microbiome, precision medicine and cancer

Analysis

Alantra's ranking of the fastest growing private pharmaceutical companies in the UK

Oli Hudson looks at what the data tells us
so far

COVID-19 and pharma's performance on access to medicine

The effect of the pandemic on lung cancer care and lessons from Europe

SmartPeople

Ipsen Pharmaceuticals' Dr Myles Furnace on overcoming diagnostic challenges in rare diseases through innovative digital partnerships

Accenture's UK and Ireland Life Sciences lead discusses the opportunities and challenges triggered by COVID-19

Novartis' Mike Fraser on the need for adaptive regulatory frameworks in 2021